OBJECTIVE: This first-in-human, randomized, double-blind, placebo-controlled trial assessed the safety of NNC0114-0005, a human recombinant anti interleukin (IL)-21 monoclonal antibody, for the treatment of rheumatoid arthritis (RA). METHODS AND MATERIALS: Healthy male subjects (HS (n = 44)) andpatients with active RA treated withmethotrexate (n = 20) were randomized 3 : 1 to single IV or SC doses of NNC0114-0005 (0.0025 - 25 mg/kg) or placebo. Safety endpoints, pharmacokinetics, and pharmacodynamics were assessed over 12 weeks. RESULTS: All study participants were analyzed. 37 AEs were reported in 21 NNC0114-0005-treated participants (44%) and 18 AEs in 10 placebo-treated participants (63%), with no dose-dependency. The most common AEs were headache and nasopharyngitis; there were no injection-site reactions Linear pharmacokinetics of NNC0114-0005 were indicated (mean terminal half-life, 2 - 3 weeks). Dose-dependent total IL-21 (freeIL-21 and IL-21‒NNC0114-0005 complexes) accumulation was observed. Preliminary signs of reduced RA activity were observed with 25 mg/kg NNC0114-0005. CONCLUSIONS: Single doses of NNC0114-0005 (≤ 25 mg/kg IV; ≤ 4 mg/kg SC) were well tolerated in HS and patients with RA. Accumulation of IL-21-containing complexes suggests neutralization of the target cytokine. Based< on this trial, further trials to explore the efficacy of anti-IL-21 were initiated.
RCT Entities:
OBJECTIVE: This first-in-human, randomized, double-blind, placebo-controlled trial assessed the safety of NNC0114-0005, a human recombinant anti interleukin (IL)-21 monoclonal antibody, for the treatment of rheumatoid arthritis (RA). METHODS AND MATERIALS: Healthy male subjects (HS (n = 44)) and patients with active RA treated with methotrexate (n = 20) were randomized 3 : 1 to single IV or SC doses of NNC0114-0005 (0.0025 - 25 mg/kg) or placebo. Safety endpoints, pharmacokinetics, and pharmacodynamics were assessed over 12 weeks. RESULTS: All study participants were analyzed. 37 AEs were reported in 21 NNC0114-0005-treated participants (44%) and 18 AEs in 10 placebo-treated participants (63%), with no dose-dependency. The most common AEs were headache and nasopharyngitis; there were no injection-site reactions Linear pharmacokinetics of NNC0114-0005 were indicated (mean terminal half-life, 2 - 3 weeks). Dose-dependent total IL-21 (free IL-21 and IL-21‒NNC0114-0005 complexes) accumulation was observed. Preliminary signs of reduced RA activity were observed with 25 mg/kg NNC0114-0005. CONCLUSIONS: Single doses of NNC0114-0005 (≤ 25 mg/kg IV; ≤ 4 mg/kg SC) were well tolerated in HS and patients with RA. Accumulation of IL-21-containing complexes suggests neutralization of the target cytokine. Based< on this trial, further trials to explore the efficacy of anti-IL-21 were initiated.
Authors: Wilhelmina Maria Cornelia Timmermans; Jan Alexander Michael van Laar; Petrus Martinus van Hagen; Menno Cornelis van Zelm Journal: Clin Transl Immunology Date: 2016-12-16
Authors: Nicole M van Besouw; Lin Yan; Ronella de Kuiper; Mariska Klepper; Derek Reijerkerk; Marjolein Dieterich; Dave L Roelen; Frans H J Claas; Marian C Clahsen-van Groningen; Dennis A Hesselink; Carla C Baan Journal: Front Immunol Date: 2019-04-09 Impact factor: 7.561
Authors: Sherene Lattimore; Nicholas J Skill; Mary A Maluccio; Holly Elliott; Elizabeth Dobben; Asif Shafuddin; William C Goggins Journal: Transplant Direct Date: 2019-09-27
Authors: Azra Hussaini; Rajat Mukherjee; Dina M Berdieva; Christen Glogowski; Richard Mountfield; Peter T C Ho Journal: Clin Transl Sci Date: 2019-11-29 Impact factor: 4.689